nach oben

Erschienen in:

07.11.2019 | Alopezie | Zertifizierte Fortbildung

Hauterkrankung und Psyche

Psychopharmakotherapie bei dermatologischen Erkrankungen

verfasst von: Prof. Dr. med. Thomas Messer, Larissa Haag, Prof. Dr. med. Georg Juckel, Dr. Paraskevi Mavrogiorgou

Erschienen in: NeuroTransmitter | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Viele dermatologische Erkrankungen treten bei Komorbiditäten mit psychischen Störungen auf, umgekehrt gibt es eine Reihe primär psychischer Erkrankungen mit dermatologischem Symptombezug. Da sowohl die Pharmakotherapie dermatologischer Erkrankungen mit psychischen als auch die Psychopharmakotherapie häufig mit dermatologischen Symptomen verbunden ist, sind bei der Psychopharmakotherapie dermatologischer Patienten pharmakokinetische und -dynamische Wechselwirkungen relevant.

Mavrogiorgou P, Juckel G. Dermatologische Erkrankungen und ihre Bedeutung für die Psychiatrie. Der Nervenarzt 2017; 88: 254–67CrossRefPubMed

Taube KM, Augustin M, Freudenmann R, Gass S, Gieler U, Harth W et al. S1 Leitlinie Psychosomatische Dermatologie; 2018

Leon A, Levin EC, Koo JY. Psychodermatology: an overview. Semin Cutan Med Surg 2013; 32: 64–7CrossRefPubMed

Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4: 833–42CrossRefPubMed

Wessely SC, Lewis GH. The classification of psychiatric morbidity in attenders at a dermatology clinic. Br J Psychiatry 1989; 155: 686–91CrossRefPubMed

Aktan S, Ozmen E, Sanli B. Psychiatric disorders in patients attending a dermatology outpatient clinic. Dermatology 1998; 197: 230–4CrossRefPubMed

Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000; 143: 983–91CrossRefPubMed

Koo J, Lebwohl A. Psycho dermatology: the mind and skin connection. Am Fam Physician 2001; 64: 1873–8PubMed

Moftah NH, Kamel AM, Attia HM, El-Baz MZ, Abd El-Moty HM. Skin diseases in patients with primary psychiatric conditions: a hospital based study. J Epidemiol Glob Health 2013; 3: 131–8CrossRefPubMedPubMedCentral

10.

Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984–91CrossRefPubMedPubMedCentral

11.

Mookhoek EJ, Van De Kerkhof PC, Hovens JE, Brouwers JR, Loonen AJ. Skin disorders in chronic psychiatric illness. J Eur Acad Dermatol Venereol 2010; 24: 1151–6CrossRefPubMed

12.

Shenefelt PD. Therapeutic management of psychodermatological disorders. Expert Opin Pharmacother 2008; 9: 973–85CrossRefPubMed

13.

Chiu A, Chon SY, Kimball AB. The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. Arch Dermatol 2003; 139: 897–900CrossRefPubMed

14.

Harth W, Gieler U, Kusnir D, Tausk FA. Clinical Management in Psychodermatology Springer Berlin Heidelberg; 2008

15.

Vallerand IA, Lewinson RT, Parsons LM, Lowerison MW, Frolkis AD, Kaplan GG et al. Risk of depression among patients with acne in the U.K.: a population-based cohort study. Br J Dermatol 2018; 178: e194–e5CrossRefPubMed

16.

Gupta MA, Gupta AK, Ellis CN, Koblenzer CS. Psychiatric evaluation of the dermatology patient. Dermatol Clin 2005; 23: 591–9CrossRefPubMed

17.

Saitta P, Keehan P, Yousif J, Way BV, Grekin S, Brancaccio R. An update on the presence of psychiatric comorbidities in acne patients, Part 2: Depression, anxiety, and suicide. Cutis 2011; 88: 92–7PubMed

18.

Strahan JE, Raimer S. Isotretinoin and the controversy of psychiatric adverse effects. Int J Dermatol 2006; 45: 789–99CrossRefPubMed

19.

Oliveira JM, Sobreira G, Velosa J, Telles Correia D, Filipe P. Association of Isotretinoin With Depression and Suicide: A Review of Current Literature. J Cutan Med Surg 2018; 22: 58–64CrossRefPubMed

20.

Hull PR, D’Arcy C. Acne, depression, and suicide. Dermatol Clin 2005; 23: 665–74CrossRefPubMed

21.

Nevoralova Z, Dvorakova D. Mood changes, depression and suicide risk during isotretinoin treatment: a prospective study. Int J Dermatol 2013; 52: 163–8CrossRefPubMed

22.

Schaffer LC, Schaffer CB, Hunter S, Miller A. Psychiatric reactions to isotretinoin in patients with bipolar disorder. J Affect Disord 2010; 122: 306–8CrossRefPubMed

23.

Mina S, Jabeen M, Singh S, Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J Dermatol 2015; 60: 211PubMedPubMedCentral

24.

Dieris-Hirche J, Gieler U, Kupfer JP, Milch WE. [Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis]. Hautarzt 2009; 60: 641–6CrossRefPubMed

25.

Savin JA, Paterson WD, Adam K, Oswald I. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol 1979; 115: 313–5CrossRefPubMed

26.

Stander S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger TA et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol} 2009; 89: 45–51

27.

Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50: 889–91CrossRefPubMed

28.

Mahtani R, Parekh N, Mangat I, Bhalerao S. Alleviating the itch-scratch cycle in atopic dermatitis. Psychosomatics 2005; 46: 373–4CrossRefPubMed

29.

Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med 2002; 64: 835–40PubMed

30.

Finzi A, Colombo D, Caputo A, Andreassi L, Chimenti S, Vena G et al. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. J Eur Acad Dermatol Venereol 2007; 21: 1161–9CrossRefPubMed

31.

Hunter HJ, Griffiths CE, Kleyn CE. Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol 2013; 169: 965–74CrossRefPubMed

32.

Nicholas MN, Gooderham M. Psoriasis, Depression, and Suicidality. Skin Therapy Letter 2017; 22: 1–4PubMed

33.

Alpsoy E, Ozcan E, Cetin L, Ozgur O, Er H, Yilmaz E et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol 1998; 38: 197–200CrossRefPubMed

34.

Thorslund K, Svensson T, Nordlind K, Ekbom A, Fored CM. Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study. J Intern Med 2013; 274: 281–7CrossRefPubMed

35.

Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004; 51: 241–8CrossRefPubMed

36.

Dadic-Hero E, Ruzic K, Grahovac T, Graovac M, Palijan TZ, Sepic-Grahovac D. Allergic reactions—outcome of sertraline and escitalopram treatments. Psychiatr Danub 2011; 23: 120–2PubMed

37.

Lessa Lda R, Luz FB, De Rezende RM, Duraes SM, Harrison BJ, De Menezes GB et al. The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology. J Psychiatr Pract 2014; 20: 316–23CrossRefPubMed

38.

Vythilingum B, Stein DJ. Obsessive-compulsive disorders and dermatologic disease. Dermatol Clin 2005; 23: 675–80CrossRefPubMed

39.

Kestenbaum T. Obsessive-compulsive disorder in dermatology. Semin Cutan Med Surg 2013; 32: 83–7CrossRefPubMed

40.

Mavrogiorgou P, Bader A, Stockfleth E, Juckel G. Zwangsstörungen in der Dermatologie. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2015; 13: 991–1000PubMed

41.

Wong JW, Nguyen TV, Koo JY. Primary psychiatric conditions: dermatitis artefacta, trichotillomania and neurotic excoriations. Indian J Dermatol 2013; 58: 44–8CrossRefPubMedPubMedCentral

42.

Huynh M, Gavino AC, Magid M. Trichotillomania. Semin Cutan Med Surg 2013; 32: 88–94CrossRefPubMed

43.

Flessner CA. Diagnosis and Comorbidity. In: Grant J, (Hrsg.). Trichotillomania, Skin Picking, and Other Body-Focused Repetitive Behaviors. Arlington: American Psychiatric Publishing, 2012;83–96

44.

Grant JE, Chamberlain SR. Trichotillomania. Am J Psychiatry 2016; 173: 868–74CrossRefPubMedPubMedCentral

45.

Adewuya EC, Zinser W, Thomas C. Trichotillomania: a case of response to valproic acid. J Child Adolesc Psychopharmacol 2008; 18: 533–6CrossRefPubMed

46.

Lochner C, Seedat S, Niehaus DJ, Stein DJ. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol 2006; 21: 255–9CrossRefPubMed

47.

Gupta MA. Emotional regulation, dissociation, and the self-induced dermatoses: clinical features and implications for treatment with mood stabilizers. Clin Dermatol 2013; 31: 110–7CrossRefPubMed

48.

Christenson GA, Popkin MK, Mackenzie TB, Realmuto GM. Lithium treatment of chronic hair pulling. J Clin Psychiatry 1991; 52: 116–20PubMed

49.

Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2010; 71: 1336–43CrossRefPubMed

50.

White MP, Koran LM. Open-label trial of aripiprazole in the treatment of trichotillomania. J Clin Psychopharmacol 2011; 31: 503–6CrossRefPubMed

51.

Gieler U, Consoli SG, Tomas-Aragones L, Linder DM, Jemec GB, Poot F et al. Self-inflicted lesions in dermatology: terminology and classification-a position paper from the European Society for Dermatology and Psychiatry (ESDaP). Acta Derm Venereol 2013; 93: 4–12CrossRefPubMed

52.

Odlaug BL, Grant JE. Pathological Skin Picking. In: Grant J, (Hrsg.). Trichotillomania, Skin Picking, and Other Body-Focused Repetitive Behaviors. Arlington: American Psychiatric Publishing, 2012;21–42

53.

Selles RR, McGuire JF, Small BJ, Storch EA. A systematic review and meta-analysis of psychiatric treatments for excoriation (skin-picking) disorder. Gen Hosp Psychiatry 2016; 41: 29–37CrossRefPubMed

54.

Grant JE, Odlaug BL, Chamberlain SR, Kim SW. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol 2010; 30: 396–403CrossRefPubMedPubMedCentral

55.

Gupta MA. Suicide risk and skin diseases. In: Berman J, Pompili M, (Hrsg.). Medical Conditions Associated With Suicide Risk. Washington DC: American Association of Suicidology, 2011;667–90

56.

Mavrogiorgou P, Juckel G. Skin Diseases in Primary Psychiatric Disorders. Fortschr Neurol Psychiatr 2016; 84: 608–16CrossRefPubMed

57.

Pearson ML, Selby JV, Katz KA, Cantrell V, Braden CR, Parise ME et al. Clinical, epidemiologic, histopathologic and molecular features of an unexplained dermopathy. PLoS One 2012; 7: e29908CrossRefPubMedPubMedCentral

58.

Malick F, Howard J, Koo J. Understanding the psychology of the cosmetic patients. Dermatol Ther 2008; 21: 47–53CrossRefPubMed

59.

Angelakis I, Gooding PA, Panagioti M. Suicidality in body dysmorphic disorder (BDD): A systematic review with meta-analysis. Clin Psychol Rev 2016; 49: 55–66CrossRefPubMed

60.

Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev 2009: CD005332

61.

Azoulay L, Blais L, Koren G, LeLorier J, Berard A. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry 2008; 69: 526–32CrossRefPubMed

62.

Borovaya A, Olisova O, Ruzicka T, Sardy M. Does isotretinoin therapy of acne cure or cause depression? Int J Dermatol 2013; 52: 1040–52CrossRefPubMed

63.

Marron SE, Tomas-Aragones L, Boira S. Anxiety, depression, quality of life and patient satisfaction in acne patients treated with oral isotretinoin. Acta Derm Venereol 2013; 93: 701–6CrossRefPubMed

64.

Thomas KH, Martin RM, Potokar J, Pirmohamed M, Gunnell D. Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacol Toxicol 2014; 15: 54CrossRefPubMedPubMedCentral

65.

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006 Jan 7;367(9504):29–35CrossRefPubMed

66.

Bassukas ID, Hyphantis T, Gamvroulia C, Gaitanis G, Mavreas V. Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity. J Eur Acad Dermatol Venereol 2008 Feb;22(2):257–8 2008PubMed

67.

Langley et al. 2010

68.

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063–70CrossRefPubMed

69.

Atigari OV, Healy D. Schizophrenia-like disorder associated with etanercept treatment. BMJ Case Rep 2014 Jan 13;2014

70.

Austin M, Tan YC. Mania associated with infliximab. Aust NZ J Psychiatry 2012;46:684–685CrossRef

71.

Elisa B, Beny L. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab. Psychiatry Clin Neurosci 2010 Aug;64(4):442–3CrossRefPubMed

72.

Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R, Skinner J, Bennett JE. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis 2014 Jun 15;209(12):1941–8CrossRefPubMedPubMedCentral

73.

Goldberg JF, Ernst CL, Stahl SM. Managing the Side Effects of Psychotropic Medications, Second Edition American Psychiatric Association Publishing; 2018

74.

McKinney PA, Finkenbine RD, DeVane CL. Alopecia and mood stabilizer therapy. Ann Clin Psychiatry 1996;8: 183–5CrossRefPubMed

75.

Lu BY, Cullen CE, Eide CE, Williams CC, Apfeldorf WJ. Antidepressant-induced sweating alleviated by aripiprazole. J Clin Psychopharmacol 2008; 28: 710–1CrossRefPubMed

76.

Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthal-mia: Report of two cases in children. Am J Dis Child 1922; 24: 526–33CrossRef

Titel: Hauterkrankung und Psyche
Psychopharmakotherapie bei dermatologischen Erkrankungen
verfasst von: Prof. Dr. med. Thomas Messer
Larissa Haag
Prof. Dr. med. Georg Juckel
Dr. Paraskevi Mavrogiorgou
Publikationsdatum: 07.11.2019
Verlag: Springer Medizin
Schlagwörter: Alopezie
Psychopharmakotherapie
Affektive Störungen
Affektive Störungen
Akne
Hyperhidrose
Erschienen in: NeuroTransmitter / Ausgabe 11/2019
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI: https://doi.org/10.1007/s15016-019-6602-2

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

MS: Hinweise auf gebremsten Hirnvolumenverlust durch S1P-R-Agonisten

Hochfunktionaler Autismus bei Erwachsenen

AOK will Patientenrechte weiter stärken

Der BVDP wird 20 Jahre — Rückblick, Ausblick, Durchblick

DMP Depression — Fachärzte nur für schwere Fälle vorgesehen

Die „drei verdächtigen A’s“ und ein veritabler Gesundheits-Politkrimi